Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and Toripalimab Combined With TACE in Unresectable HCC
NCT04605185Phase 1Active, not recruiting
- Sponsor
- Zelgen
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Zelgen. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Jan 2021; status: active, not recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04605185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605185.